Stock MDP MEDEXUS PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.59 CAD -5.92% Intraday chart for Medexus Pharmaceuticals Inc. -11.17% -35.63%
Mar. 26 Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R) CI
Feb. 09 Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85 MT

Business Summary

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.

Number of employees: 98

Sales per Business

CAD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
96 100.0 % 143 100.0 % +48.72%

Sales per region

CAD in Million2022Weight2023Weight Delta
United States
73.0 %
65 67.8 % 104 73.0 % +60.18%
Canada
27.0 %
31 32.2 % 39 27.0 % +24.58%

Managers

Managers TitleAgeSince
Kenneth d’Entremont CEO
 Chief Executive Officer - 18-10-15
Marcel Konrad DFI
 Director of Finance/CFO 49 21-07-18
Richard Labelle COO
 Chief Operating Officer - 14-02-17
Ian Wildgoose Brown LAW
 General Counsel - 21-11-07

Members of the board

Members of the board TitleAgeSince
Adele Gulfo BRD
 Director/Board Member 61 19-06-24
Michael Mueller CHM
 Chairman 64 14-05-30
Benoit Gravel BRD
 Director/Board Member - 17-09-21
Kenneth d’Entremont CEO
 Chief Executive Officer - 18-10-15
Nancy Phelan BRD
 Director/Board Member 55 23-09-20
Stephen Nelson BRD
 Director/Board Member - 18-10-15
Menassie Taddese BRD
 Director/Board Member - 23-02-05
Harmony Garges BRD
 Director/Board Member - 23-02-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 24,458,213 22,267,371 ( 91.04 %) 0 91.04 %

Shareholders

NameEquities%Valuation
Armistice Capital LLC
6.280 %
1,536,000 6.280 % 2 M $
Kenneth d’Entremont
5.977 %
1,461,889 5.977 % 2 M $
Stephen Nelson
2.237 %
547,080 2.237 % 666 891 $
Michael Mueller
0.3634 %
88,870 0.3634 % 108 333 $
Marcel Konrad
0.3272 %
80,021 0.3272 % 97 546 $
Goodwood, Inc.
0.2699 %
66,024 0.2699 % 80 483 $
Benoit Gravel
0.2304 %
56,358 0.2304 % 68 700 $
Adele Gulfo
0.2246 %
54,930 0.2246 % 66 960 $
Michael D. Adelman
0.1178 %
28,800 0.1178 % 35 107 $
Ian Wildgoose Brown
0.0844 %
20,634 0.0844 % 25 153 $

Company contact information

Medexus Pharmaceuticals, Inc.

35 Nixon Road Unit 1

L7E 1K1, Bolton

+877-633-3987

http://www.medexusinc.com
address Medexus Pharmaceuticals Inc.(MDP)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Medexus Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.59 CAD
Average target price
3.208 CAD
Spread / Average Target
+101.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MEDEXUS PHARMACEUTICALS INC. Stock Medexus Pharmaceuticals Inc.
-35.63% 28.46M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MDP Stock
  4. Company Medexus Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW